Antiviral drug

AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

Retrieved on: 
Monday, June 13, 2022
Netherlands Patent Office, Human, Utah State University, EAP, Biomarker, PCT, Coronavirus, Outcome (probability), Company, COVID, Lists of diseases, Research, Antiviral drug, Infection, Survival, Fatigue, ORR, Patent, Invention, Severe acute respiratory syndrome coronavirus, Immunity, American, RNA, Cancer, Disease, Biological patent, AIM, Pancreatic cancer, Therapy, Cisplatin, Ovarian cancer, Pembrolizumab, Method, GLOBE, Patient, Mortality, Tumor microenvironment, Health, PLOS, NYSE, COVID-19, Immune system, Nivolumab, Food and Drug Administration, Severe acute respiratory syndrome coronavirus 2, Patent Cooperation Treaty, Degenerative disease, Interim, The Institute, Safety, Pharmaceutical industry, Vaccine, ME/CFS, Rintatolimod

2027383 a utility patent covering Ampligen (rintatolimod) and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041.

Key Points: 
  • 2027383 a utility patent covering Ampligen (rintatolimod) and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041.
  • Ampligen is AIMs RNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • In another patent embodiment, the therapeutic double-stranded RNA product may be one or more of a number of therapeutic double-stranded RNA (tdsRNA) developed by AIM.
  • National patent application filings based on these PCTs, entitled to claim priority from the provisional patent applications, are ongoing.

Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19

Retrieved on: 
Tuesday, April 19, 2022
CEO, PCC, Investigational New Drug, IND, COVID-19, HBV, NASH, Permeability, Human, IIT Research Institute, Illinois Institute of Technology, Fatty liver disease, Primary biliary cholangitis, Conference, Glutamic acid, PBC, ICAR, Antiviral drug, Company, Degenerative disease, Metabolism, MedRxiv, EC50, Epithelium, Organic acid, Hong Kong Stock Exchange, Safety, Acne, International Conference on Emerging Infectious Diseases, BioRxiv, Severe acute respiratory syndrome coronavirus 2, Caco-2, Vaccine, Mobile phone, Pharmaceutical industry, Technology

HANGZHOU, China and SHAOXING, China, April 19, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that its oral small molecule drug candidate ASC11, a 3-chymotrypsin like protease (3CLpro) inhibitor, demonstrated potential to be effective treatment for COVID-19.

Key Points: 
  • EC90:a measure of drug potency showing a concentration that is effective in producing 90% of the maximal virus reduction.
  • Compared to EC50 (a concentration that is effective in producing 50% of the maximal virus reduction), EC90 can predict more precisely the effective concentration of an antiviral drug in humans.
  • Molecular docking showed ASC11 bound to 3CLpro differently from S-217622, resulting in much higher antiviral potency (EC90) of ASC11.
  • Together with other preclinical data including Caco-2 permeability, in vitro metabolism, microsomal stability and animal pharmacokinetic studies, ASC11 demonstrated potential for best-in-class antiviral treatment of COVID-19.

Global Antimicrobial, Antiviral and Antifungal Nanocoatings Market Report 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 8, 2022
Medical Supplies, Health, Virus, Life, Fungus, Nano, Glass, Health, Alloy, Nanoco, City, Bacteria, Nanoparticle, Plastic, Hospital, Stainless steel, School, Immune system, Textile, Formaldehyde, Industry, Corrosion, COVID-19, Mark (given name), Ceramic, Copper, Metal, Maintenance, Hotel, Water, Vaccine, Food preservation, Antiviral drug

The "Global Market for Antimicrobial, Antiviral and Antifungal Nanocoatings 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Antimicrobial, Antiviral and Antifungal Nanocoatings 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • Nanocoatings can demonstrate up to 99.9998% effectiveness against bacteria, formaldehyde, mould and viruses, and are up to 1000 times more efficient than previous technologies available on the market.
  • They can work on multiple levels at the same time: anti-microbial, anti-viral, anti-fungal, self-cleaning and anti-corrosion.
  • Antimicrobial, antiviral and antifungal nanocoatings applications include, but are not limited to:

Worldwide Infectious Disease Treatment Industry to 2029 - Rising Demand for Personalized Medication is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 29, 2022
Health, Infectious Diseases, Hepatitis B, Antiviral drug, Therapy, HPV, Delafloxacin, AIDS, Infection, Global Infectious Disease Epidemiology Network, Cadazolid, Hepatitis C, MRSA, Pharmaceutical industry

The pipeline analysis for global infectious disease treatment market comprises projected market sales of Phase III anti-infective drugs estimated till 2029.

Key Points: 
  • The pipeline analysis for global infectious disease treatment market comprises projected market sales of Phase III anti-infective drugs estimated till 2029.
  • The geographic segmentation of the global infectious disease treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets.
  • The regions are also further sub-segmented on the basis of major countries.
  • Market size estimates and forecast for these segments for the period 2019 to 2029 are provided in terms of US$ Mn along with the respective CAGRs for the period 2019 to 2029, considering 2020 as the base year.

Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors

Retrieved on: 
Monday, December 20, 2021
Therapy, Antiviral drug, TGF, Doctor of Philosophy, SAN, STI, Acquisition, Risk, TRPV1, MBA, Interleukin, Trial of the century, Antibody, Senior, 1386, Forward-looking statement, NK, FDA, Oncolytic herpes virus, Pain, Safety, Cancer, Tumor microenvironment, U.S. Securities and Exchange Commission, Vaccine, Security (finance), MD, GLOBE, Sarcoma, JD, Relapse, Autoimmune disease, Cell, RTX, Sciatica, Herpes labialis, Osteoarthritis, Trigeminal neuralgia, Transgene, Food, Private Securities Litigation Reform Act, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Pharmaceutical industry, Generic drug, Patient, COVID-19

STI-1386, or Seprehvec, is a 2nd generation oncolytic herpes simplex virus type 1 (oHSV) developed following the acquisition of Virttu Biologics by Sorrento in 2017 and produced in Sorrentos GMP virus therapeutics manufacturing facility.

Key Points: 
  • STI-1386, or Seprehvec, is a 2nd generation oncolytic herpes simplex virus type 1 (oHSV) developed following the acquisition of Virttu Biologics by Sorrento in 2017 and produced in Sorrentos GMP virus therapeutics manufacturing facility.
  • Seprehvec additionally expresses transgenes encoding an anti-PD-1 scFv-Fc isolated from the Sorrento G-MAB antibody library, a TGF beta receptor 2 decoy, and interleukin-12.
  • Seprehvec allows for locoregional immune stimulation at the tumor site while potentially minimizing the undesired effects that may accompany systemic immune stimulation.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.

Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treatment of COVID-19

Retrieved on: 
Tuesday, November 9, 2021
Safety, Dermatology, Science, Private Securities Litigation Reform Act, GLP, Novin, Security (finance), Institute, Disease, Technology, Utah, Antiviral drug, CTAP, RSV, Severe acute respiratory syndrome coronavirus 2, Coronavirus, COVID-19, Research, Forward-looking statement, Animal, Intention, Human, Annual report, Utah State University, Company, U.S. Securities and Exchange Commission, GLOBE, NCE, New chemical entity, Toxicity, Lung, Patient, Risk, FDA, IND, Vaccine, Pharmaceutical industry

DURHAM, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced promising preclinical safety results with berdazimer sodium in a 14-day GLP repeat dose intranasal toxicity study. These findings compliment the previous positive preclinical efficacy results observed in deterring transmission from SARS-CoV-2-infected golden Syrian hamsters. The Company is continuing to progress the development of its potential anti-viral therapy against COVID-19, the disease caused by the SARS-CoV-2 virus.

Key Points: 
  • These findings compliment the previous positive preclinical efficacy results observed in deterring transmission from SARS-CoV-2-infected golden Syrian hamsters.
  • To further evaluate the potential of its NITRICIL platform technology as an intranasal treatment option for COVID-19, the Company initiated preclinical in vivo studies evaluating the safety and toxicity of berdazimer sodium when intranasally administered via the SB019 formulation.
  • These preclinical data support and further strengthen the rationale behind developing SB019 as a potential intranasal therapeutic against COVID-19.
  • Through engagement with the Coronavirus Treatment Acceleration Program, or CTAP, we have made the FDA aware of our SB019 program and our intent to submit an IND.

Global Hospital Acquired Infections Therapeutic Markets 2020-2027: Rise in Approval and Launch of New Drugs Bodes Well for the Market - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 20, 2021
Hospitals, Pharmaceutical, Health, SSIS, Infection, CAGR, Prevalence, Clostridioides, Merck, Ventilator-associated pneumonia, Avibactam, Shanda, Colon, Subclinical infection, New York State Department of Health, D, USD, FDA, Adoption, New Drug Application, Hospital, Clostridioides difficile infection, Eyeish, Conditional sentence, Antiviral drug, HAI, Therapy, CDI, Ceftazidime, Pharmaceutical industry

The "Global Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), by Infection Type, by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hospital Acquired Infections Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs), by Infection Type, by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global hospital acquired infections therapeutic market size is expected to reach USD 12.5 billion by 2027.
  • The market is expected to expand at a CAGR of 2.4% from 2020 to 2027.
  • The high prevalence of HAIs, rise in approval and launch of new drugs, and growing hospitalization due to the rise in prevalence of chronic diseases are driving the market.

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

Retrieved on: 
Tuesday, September 28, 2021
Food, Patent, Mortality, Clinical trial, Cancer, Ichinohe, PSLRA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Antiviral drug, Immunity, AIM, Private Securities Litigation Reform Act, Utah, Degenerative disease, FDA, Institute, Drug discovery, Lists of diseases, Company, Utah State University, Disease, Trial of the century, COVID-19, Severe acute respiratory syndrome coronavirus 2, Research, Safety, NYSE, Nasal administration, GLOBE, Pharmaceutical industry, Vaccine

In addition to studying efficacy and safety, the new Phase 2 protocols include exploratory endpoints that the company believes could support its recently filed provisional patent application.

Key Points: 
  • In addition to studying efficacy and safety, the new Phase 2 protocols include exploratory endpoints that the company believes could support its recently filed provisional patent application.
  • We believe the clearly defined exploratory endpoints for the upcoming trials will substantially validate the significant potential of Ampligen.
  • With a SARS-CoV-1 virus mouse models, Ampligen demonstrated 100% protective survival benefit compared to 100% mortality in a saline control group.
  • There is the potential for delays in clinical trial enrollment and reporting because of the COVID-19 medical emergency.

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

Retrieved on: 
Wednesday, August 25, 2021
Cancer, Company, Lists of diseases, Population, Delta, Private Securities Litigation Reform Act, Human, Therapy, Special access program, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Viral load, The Wall Street Journal, GLOBE, Method, Survival, Amnesia, Leadership, The Institute, Research, Erasmus MC, Disease, Utah, Doctor of Philosophy, PSLRA, Influenza, Severe acute respiratory syndrome coronavirus, NYSE, Clinical trial, AIM, Mortality, Safety, EAP, Patient, Immunity, Utah State University, Vaccine, Infection, Antiviral drug, COVID-19, MD, Pharmaceutical industry

Developing an effective therapy is critical for relieving the socioeconomical impact of PCCD and its medical burden on the population.

Key Points: 
  • Developing an effective therapy is critical for relieving the socioeconomical impact of PCCD and its medical burden on the population.
  • The results of some individual symptoms are very dramatic, said Lapp, the EAPs lead investigator.
  • The results clearly show a significant reduction of one or more symptoms of PCCD in patients after the administration of Ampligen.
  • The study is part of AIMs work to develop Ampligen as a potential therapy against SARS-CoV-2 and other respiratory viruses.

TCM Lianhua Qingwen shows stable in vitro antiviral effect on the Delta variant: Expert

Retrieved on: 
Tuesday, August 3, 2021
Health sciences, COVID-19 pandemic in China, Lianhua Qingwen, Pharmaceutical sciences, Life sciences, Antiviral drug, Medication, SARS-CoV-2 Delta variant, Delta, Lianhua, Pharmaceutical industry

Yang mentioned that focusing on the development of Delta variant, his team had been researching its diagnosis, medication, and prevention.

Key Points: 
  • Yang mentioned that focusing on the development of Delta variant, his team had been researching its diagnosis, medication, and prevention.
  • As to the medication, the drugs which played a critical role in 2020 still work in dealing with Delta variant, for instance, the Lianhua Qingwen Capsules developed and produced by Yiling Pharmaceutical, and some monomers extracted from herbs.
  • Experiments show that these drugs all have inhibition functions against the Delta variant, and Lianhua Qingwen has displayed obvious and stable in-vitro antiviral functions against both Alpha, Beta, and Delta variant.
  • What the State Key Laboratory of Respiratory Disease in Guangzhou is doing now also includes the research and development of vaccines, and how to integrate the use of drugs such as Lianhua Qingwen and vaccination to provide double protection for people.